Mobile Site ›

Interpretive Handbook

‹ Back to index | Back to list | More information

Test 8342 :
Hepatitis A IgM Antibody, Serum

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Hepatitis A virus (HAV) is endemic throughout the world, occurring most commonly, however, in areas of poor hygiene and low socioeconomic conditions. The virus is transmitted primarily by the fecal-oral route, and it is spread by close person-to-person contact and by food- and water-borne epidemics. Outbreaks frequently occur in overcrowded situations and in high-density institutions and centers, such as prisons and health care or day care centers. Viral spread by parenteral routes (eg, exposure to blood) is possible but rare, because infected individuals are viremic for a short period of time (usually <3 weeks). There is little or no evidence of transplacental transmission from mother to fetus or transmission to newborn during delivery.

 

Serological diagnosis of acute viral hepatitis A depends on the detection of specific anti-HAV IgM. Its presence in the patient's serum indicates a recent exposure to HAV. Anti-HAV IgM becomes detectable in the blood within 2 weeks after infection, persisting at elevated levels for about 2 months before declining to undetectable levels by 6 months. However, sensitive immunoassays may occasionally detect anti-HAV IgM for up to 1 year after acute hepatitis A.

Useful For Suggests clinical disorders or settings where the test may be helpful

Diagnosis of acute or recent hepatitis A infection

Interpretation Provides information to assist in interpretation of the test results

A positive result indicates acute or recent (<6 months) hepatitis A infection. As required by laws in almost all states, positive antihepatitis A virus (anti-HAV) IgM test results must be urgently reported to state health departments for epidemiologic investigations of possible outbreak transmission.

 

A negative result may indicate either 1) inadequate or delayed HAV IgM response after known exposure to HAV, or 2) absence of acute or recent hepatitis A.

 

Borderline anti-HAV IgM test results may be seen in: 1) early acute hepatitis A associated with rising antibody levels, 2) recent hepatitis A associated with declining levels, or 3) cross-reactivity with nonspecific antibodies (ie, false-positive results). Retesting of both anti-HAV IgM (HAVM / Hepatitis A IgM Antibody, Serum) and anti-HAV total (HAV / Hepatitis A Total Antibodies, Serum) in 2 to 4 weeks is recommended to determine the definitive HAV infection status.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

False-positive test results may be due to presence of cross-reactive antibodies from other viral infection or underlying illnesses. Positive results should be correlated with the patient's clinical history and epidemiologic exposure. 

 

Testing too early (<2 weeks) after exposure to hepatitis A virus (HAV) may yield negative anti-HAV IgM test results.

 

Not useful for determining presence of immunity to HAV infection from either past hepatitis A or vaccination against HAV

 

Performance characteristics have not been established for the following specimen characteristics:

-Grossly icteric (total bilirubin level of >15 mg/dL)

-Grossly hemolyzed (hemoglobin level of >500 mg/dL)

-Grossly lipemic (triolein >3,000 mg/dL)

-Containing particulate matter

-Cadaveric specimens

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

Negative 

See Viral Hepatitis Serologic Profiles in Special Instructions.

Clinical References Provides recommendations for further in-depth reading of a clinical nature

1. Wasley A, Fiore A, Bell BP: Hepatitis A in the era of vaccination. Epidemiol Rev 2006;28:101-111

2. Nainan OV, Xia G, Vaughan G, Margolis HS: Diagnosis of hepatitis A infection: a molecular approach. Clin Microbiol Rev 2006;19:63-79


Key